Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms.

Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, Okamoto I, Kim JY, Song L, Bai Y, Qian X, Rawal B, Schell M, Grebien F, Winter G, Rix U, Eschrich S, Colinge J, Koomen J, Superti-Furga G, Haura EB.

Mol Syst Biol. 2013 Nov 5;9:705. doi: 10.1038/msb.2013.61.

2.

Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.

Fong JT, Jacobs RJ, Moravec DN, Uppada SB, Botting GM, Nlend M, Puri N.

PLoS One. 2013 Nov 4;8(11):e78398. doi: 10.1371/journal.pone.0078398. eCollection 2013.

3.

CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.

Park KS, Raffeld M, Moon YW, Xi L, Bianco C, Pham T, Lee LC, Mitsudomi T, Yatabe Y, Okamoto I, Subramaniam D, Mok T, Rosell R, Luo J, Salomon DS, Wang Y, Giaccone G.

J Clin Invest. 2014 Jul;124(7):3003-15. doi: 10.1172/JCI73048. Epub 2014 Jun 9.

4.
5.

The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.

Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, Yang SH, Lee SS, Kim CH, Yoo YD, Lee JC.

Mol Cancer Res. 2009 Oct;7(10):1736-43. doi: 10.1158/1541-7786.MCR-08-0504. Epub 2009 Oct 6.

6.

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han R, Wang X, Zhong D, Zhao J, Chen Z, Sun L, Wang J, Zhang J.

Zhongguo Fei Ai Za Zhi. 2012 Dec;15(12):689-93. doi: 10.3779/j.issn.1009-3419.2012.12.02. Chinese.

7.

The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.

Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S.

Int J Cancer. 2013 Jul 15;133(2):505-13. doi: 10.1002/ijc.28034. Epub 2013 Feb 12.

8.
9.

Stem cell-like ALDH(bright) cellular states in EGFR-mutant non-small cell lung cancer: a novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin.

Corominas-Faja B, Oliveras-Ferraros C, Cuyàs E, Segura-Carretero A, Joven J, Martin-Castillo B, Barrajón-Catalán E, Micol V, Bosch-Barrera J, Menendez JA.

Cell Cycle. 2013 Nov 1;12(21):3390-404. doi: 10.4161/cc.26417. Epub 2013 Sep 17.

10.

Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.

Qu G, Liu C, Sun B, Zhou C, Zhang Z, Wang P.

Oncol Rep. 2014 Jul;32(1):341-7. doi: 10.3892/or.2014.3178. Epub 2014 May 15.

PMID:
24842595
11.

Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.

Okamoto K, Okamoto I, Hatashita E, Kuwata K, Yamaguchi H, Kita A, Yamanaka K, Ono M, Nakagawa K.

Mol Cancer Ther. 2012 Jan;11(1):204-13. doi: 10.1158/1535-7163.MCT-11-0638. Epub 2011 Nov 10.

12.

Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.

Togashi Y, Hayashi H, Okamoto K, Fumita S, Terashima M, de Velasco MA, Sakai K, Fujita Y, Tomida S, Nakagawa K, Nishio K.

Lung Cancer. 2015 Apr;88(1):16-23. doi: 10.1016/j.lungcan.2015.01.027. Epub 2015 Feb 7.

PMID:
25704955
13.

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.

Zhang Y, Yao K, Shi C, Jiang Y, Liu K, Zhao S, Chen H, Reddy K, Zhang C, Chang X, Ryu J, Bode AM, Dong Z, Dong Z.

Oncotarget. 2015 Dec 29;6(42):44274-88. doi: 10.18632/oncotarget.6236.

14.

Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.

Sakuma Y, Nishikiori H, Hirai S, Yamaguchi M, Yamada G, Watanabe A, Hasegawa T, Kojima T, Niki T, Takahashi H.

Lab Invest. 2016 Apr;96(4):391-8. doi: 10.1038/labinvest.2015.155. Epub 2016 Jan 11.

15.

Noncovalent wild-type-sparing inhibitors of EGFR T790M.

Lee HJ, Schaefer G, Heffron TP, Shao L, Ye X, Sideris S, Malek S, Chan E, Merchant M, La H, Ubhayakar S, Yauch RL, Pirazzoli V, Politi K, Settleman J.

Cancer Discov. 2013 Feb;3(2):168-81. doi: 10.1158/2159-8290.CD-12-0357. Epub 2012 Dec 10.

16.

Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.

Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S.

Mol Cancer Ther. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Epub 2012 Jul 25.

17.

Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.

Li YY, Lam SK, Mak JC, Zheng CY, Ho JC.

Lung Cancer. 2013 Sep;81(3):354-61. doi: 10.1016/j.lungcan.2013.05.012. Epub 2013 Jun 13.

PMID:
23769318
18.

Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.

Filosto S, Baston DS, Chung S, Becker CR, Goldkorn T.

Mol Cancer Ther. 2013 Aug;12(8):1579-90. doi: 10.1158/1535-7163.MCT-12-1029. Epub 2013 May 17.

19.

The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor.

Suda K, Mizuuchi H, Sato K, Takemoto T, Iwasaki T, Mitsudomi T.

Int J Cancer. 2014 Aug 15;135(4):1002-6. doi: 10.1002/ijc.28737. Epub 2014 Feb 4.

20.

Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.

Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Jänne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV.

Clin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15.

Supplemental Content

Support Center